Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short ‐term treatment of rheumatoid arthritis: Results of two randomized Phase IIA trials

Conclusion. Selective inhibition of JAK1 by filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies. This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatism - June 16, 2017 Category: Rheumatology Authors: Fr édéric Vanhoutte, Minodora Mazur, Oleksandr Voloshyn, Mykola Stanislavchuk, Annegret Van der Aa, Florence Namour, René Galien, Luc Meuleners, Gerben van ‘t Klooster Tags: Full Length Source Type: research